These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 23334193)

  • 1. The next questions in chronic myeloid leukaemia and their answers.
    Marin D; Rotolo A; Milojkovic D; Goldman J
    Curr Opin Hematol; 2013 Mar; 20(2):163-8. PubMed ID: 23334193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current opinions and controversies in chronic myeloid leukaemia.
    Kishore B; Marin D
    Curr Opin Oncol; 2011 Nov; 23(6):659-64. PubMed ID: 21918441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimising chronic myeloid leukaemia therapy in the face of resistance to tyrosine kinase inhibitors--a synthesis of clinical and laboratory data.
    Irvine DA; Heaney NB; Holyoake TL
    Blood Rev; 2010 Jan; 24(1):1-9. PubMed ID: 20005615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Who with chronic myelogenous leukemia to transplant in the era of tyrosine kinase inhibitors?
    Maziarz RT
    Curr Opin Hematol; 2008 Mar; 15(2):127-33. PubMed ID: 18300759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current role of stem cell transplantation in chronic myeloid leukaemia.
    Gratwohl A; Heim D
    Best Pract Res Clin Haematol; 2009 Sep; 22(3):431-43. PubMed ID: 19959092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic myeloid leukemia (CML) in children: classical and newer therapeutic approaches.
    Ampatzidou M; Papadhimitriou SI; Goussetis E; Panagiotou JP; Papadakis V; Polychronopoulou S
    Pediatr Hematol Oncol; 2012 Aug; 29(5):389-94. PubMed ID: 22690835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic mutations in chronic myelogenous leukemia: when to check and what to do?
    Berman E
    Curr Opin Hematol; 2012 Mar; 19(2):110-6. PubMed ID: 22248877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment strategies for CML.
    Goldman JM
    Best Pract Res Clin Haematol; 2009 Sep; 22(3):303-13. PubMed ID: 19959082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel tyrosine kinase inhibitors in chronic myelogenous leukemia.
    Jabbour E; Cortes J; Kantarjian H
    Curr Opin Oncol; 2006 Nov; 18(6):578-83. PubMed ID: 16988578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to tyrosine kinase inhibitor therapy in patients with chronic myelogenous leukemia relapsing in chronic and advanced phase following allogeneic hematopoietic stem cell transplantation.
    Wright MP; Shepherd JD; Barnett MJ; Nantel SH; Sutherland HJ; Toze CL; Hogge DE; Nevill TJ; Song KW; Abou Mourad YR; Narayanan S; Power MM; Smith CA; Forrest DL
    Biol Blood Marrow Transplant; 2010 May; 16(5):639-46. PubMed ID: 20005967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is there a role for allogeneic transplantation in chronic myeloid leukemia?
    Benyamini N; Rowe JM
    Expert Rev Hematol; 2013 Dec; 6(6):759-65. PubMed ID: 24219552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular basis for therapeutic decisions in chronic myeloid leukemia patients after allogeneic bone marrow transplantation.
    Román J; Alvarez MA; Torres A
    Haematologica; 2000 Oct; 85(10):1072-82. PubMed ID: 11025600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing therapy of chronic myeloid leukemia.
    Deininger MW
    Exp Hematol; 2007 Apr; 35(4 Suppl 1):144-54. PubMed ID: 17379100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.
    An X; Tiwari AK; Sun Y; Ding PR; Ashby CR; Chen ZS
    Leuk Res; 2010 Oct; 34(10):1255-68. PubMed ID: 20537386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular diagnosis and monitoring of chronic myelogenous leukemia: BCR-Abl and more.
    Cea M; Cagnetta A; Garuti A; Cirmena G; Rocco I; Moran E; Grillo V; Ballestrero A; Patrone F; Nencioni A
    J BUON; 2009; 14(4):565-73. PubMed ID: 20148444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Chronic myeloid leukemia: "archetype" of the impact of targeted therapies].
    Nasr R; Bazarbachi A
    Pathol Biol (Paris); 2012 Aug; 60(4):239-45. PubMed ID: 22743097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging drugs for chronic myeloid leukemia.
    Cilloni D; Messa E; Rotolo A; Saglio G
    Expert Opin Emerg Drugs; 2010 Jun; 15(2):175-84. PubMed ID: 20201747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
    Walz C; Sattler M
    Crit Rev Oncol Hematol; 2006 Feb; 57(2):145-64. PubMed ID: 16213151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
    Wongboonma W; Thongnoppakhun W; Auewarakul CU
    Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.